Logo

nasopharyngeal cancer

Naveris, Mayo Clinic Begin Trial of Circulating Tumor DNA Test in Head and Neck Cancer

Researchers hope to establish the ability of Naveris' NavDx test to guide treatment intensity for patients with HPV-driven head and neck cancer.

Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests

The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.

Naveris Explores New Applications for ctDNA HPV Head and Neck Cancer Test
Premium

The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.

Yourgene Health to Distribute Take2 Health Nasopharyngeal Cancer Screening Test in Taiwan

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

HPV Head and Neck Cancer Recurrence Test Data Adds Validation as Naveris Ramps Clinical Launch
Premium

The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.